학술논문
Safety of jakinibs: lessons from ORAL Surveillance.
Document Type
Editorial
Author
Source
Subject
*ANTI-inflammatory agents
*MAJOR adverse cardiovascular events
*JANUS kinases
*TREATMENT effectiveness
*METHOTREXATE
*RHEUMATOID arthritis
*DRUG labeling
*NEUROTRANSMITTER uptake inhibitors
*PATIENT safety
*
*
*
*
*
*
*
*
Language
ISSN
1462-0324
Abstract
The article discusses the ORAL Surveillance study on the jakinibs methotrexate (MTX) agent's safety for major adverse cardiac events (MACE) and malignancies, excluding non-melanoma skin cancer (NMSC). Topics covered include the safety question with different ex vivo specificity for other Janus kinase enzymes, the U.S. Food and Drug Administration's (FDA) required labelling for jakinibs, and the study's alert on the serious outcome potential in rheumatoid arthritis (RA) patients.